{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:09:52Z","timestamp":1792782592497,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Natural Science Foundation of China","award":["82405007"],"award-info":[{"award-number":["82405007"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Foundation of the Jiangxi Province Department of Science and Technology Youth Project","award":["20242BAB20468"],"award-info":[{"award-number":["20242BAB20468"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00284-026-05084-w","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:42:16Z","timestamp":1786621336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment with Roseburia intestinalis Relieves Symptoms of Chronic Kidney Disease (CKD) by Altering the Gut Microbiota and Increasing the Levels of Fecal SCFAs in Adriamycin-Induced CKD Rats"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4731-888X","authenticated-orcid":false,"given":"Jinna","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqi","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1839-3765","authenticated-orcid":false,"given":"Zhentao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"5084_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 12:7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003","journal-title":"Kidney Int Suppl"},{"key":"5084_CR2","doi-asserted-by":"publisher","first-page":"155194","DOI":"10.1016\/j.metabol.2022.155194","volume":"131","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Hu J, Chen Z, Feng J, Yang X, Liang W, Ding G (2022) Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming. Metabolism 131:155194. https:\/\/doi.org\/10.1016\/j.metabol.2022.155194","journal-title":"Metabolism"},{"key":"5084_CR3","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","volume":"132","author":"M Burnier","year":"2023","unstructured":"Burnier M, Damianaki A (2023) Hypertension as cardiovascular risk factor in chronic kidney disease. Circ Res 132:1050\u20131063. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.321762","journal-title":"Circ Res"},{"key":"5084_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jama.2022.11176","volume":"328","author":"HJ Adrogue","year":"2022","unstructured":"Adrogue HJ, Tucker BM, Madias NE (2022) Diagnosis and management of hyponatremia: a review. JAMA 328:280\u2013291. https:\/\/doi.org\/10.1001\/jama.2022.11176","journal-title":"JAMA"},{"key":"5084_CR5","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI (2022) Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep 7:1463\u20131476. https:\/\/doi.org\/10.1016\/j.ekir.2022.04.094","journal-title":"Kidney Int Rep"},{"key":"5084_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.kint.2022.10.030","volume":"103","author":"S Rayego-Mateos","year":"2023","unstructured":"Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, Mora-Ferna C, Marchant V, Donate-Correa J, Navarro-Gonza JF, Ortiz A, Ruiz-Ortega M (2023) Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int 103:282\u2013296. https:\/\/doi.org\/10.1016\/j.kint.2022.10.030","journal-title":"Kidney Int"},{"key":"5084_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/nu14010166","volume":"14","author":"CO Iatcu","year":"2022","unstructured":"Iatcu CO, Steen A, Covasa M (2022) Gut microbiota and complications of type-2 diabetes. Nutrients 14:166. https:\/\/doi.org\/10.3390\/nu14010166","journal-title":"Nutrients"},{"key":"5084_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/nu15020360","volume":"15","author":"N Li","year":"2023","unstructured":"Li N, Wang Y, Wei P, Min Y, Yu M, Zhou G, Yuan G, Sun J, Dai H, Zhou E, He W, Sheng M, Gao K, Zheng M, Sun W, Zhou D, Zhang L (2023) Causal effects of specific gut microbiota on chronic kidney diseases and renal function\u2014a two-sample mendelian randomization study. Nutrients 15:360. https:\/\/doi.org\/10.3390\/nu15020360","journal-title":"Nutrients"},{"key":"5084_CR9","doi-asserted-by":"publisher","first-page":"e18991","DOI":"10.1016\/j.heliyon.2023.e18991","volume":"9","author":"S Amini Khiabani","year":"2023","unstructured":"Amini Khiabani S, Asgharzadeh M, Samadi Kafil H (2023) Chronic kidney disease and gut microbiota. Heliyon 9:e18991. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18991","journal-title":"Heliyon"},{"key":"5084_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/toxins13040252","volume":"13","author":"J Rysz","year":"2021","unstructured":"Rysz J, Franczyk B, Lawinski J, Olszewski R, Cialkowska-Rysz A, Gluba-Brzozka A (2021) The impact of CKD on uremic toxins and gut microbiota. Toxins 13:252. https:\/\/doi.org\/10.3390\/toxins13040252","journal-title":"Toxins"},{"key":"5084_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/toxins14100648","volume":"14","author":"S Bhargava","year":"2022","unstructured":"Bhargava S, Merckelbach E, Noels H, Vohra A, Jankowski J (2022) Homeostasis in the gut microbiota in chronic kidney disease. Toxins 14:648. https:\/\/doi.org\/10.3390\/toxins14100648","journal-title":"Toxins"},{"key":"5084_CR12","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1080\/10408398.2021.1874287","volume":"62","author":"J Wang","year":"2022","unstructured":"Wang J, Chen Y, Zhong H, Chen F, Regenstein J, Hu X, Cai L, Feng F (2022) The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies. Crit Rev Food Sci Nutr 62:3979\u20133989. https:\/\/doi.org\/10.1080\/10408398.2021.1874287","journal-title":"Crit Rev Food Sci Nutr"},{"key":"5084_CR13","doi-asserted-by":"publisher","first-page":"1875796","DOI":"10.1080\/19490976.2021.1875796","volume":"13","author":"X Liu","year":"2021","unstructured":"Liu X, Mao B, Gu J, Wu J, Cui S, Wang G, Zhao J, Zhang H, Chen W (2021) Blautia\u2014a new functional genus with potential probiotic properties? Gut Microbes 13:1875796. https:\/\/doi.org\/10.1080\/19490976.2021.1875796","journal-title":"Gut Microbes"},{"key":"5084_CR14","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.3390\/nu14153041","volume":"14","author":"G Ruan","year":"2022","unstructured":"Ruan G, Chen M, Chen L, Xu F, Xiao Z, Yi A, Tian Y, Ping Y, Lv L, Cheng Y, Wei YR (2022) R. intestinalis and its metabolite butyrate inhibit colitis and upregulate TLR5 through the SP3 signaling pathway. Nutrients 14:3041. https:\/\/doi.org\/10.3390\/nu14153041","journal-title":"Nutrients"},{"key":"5084_CR15","doi-asserted-by":"publisher","first-page":"973046","DOI":"10.3389\/fmicb.2022.973046","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang C, Ma K, Nie K, Deng M, Luo W, Wu X, Yang Y, Zhang B (2022) Assessment of the safety and probiotic properties of R. intestinalis: A potential \u2018Next Generation Probiotic\u2019. Front Microbiol 13:973046. https:\/\/doi.org\/10.3389\/fmicb.2022.973046","journal-title":"Front Microbiol"},{"key":"5084_CR16","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41564-018-0272-x","volume":"3","author":"K Kasahara","year":"2018","unstructured":"Kasahara K, Krautkramer KA, Org E, Romano KA, Kerby RL, Vivas EI, Mehrabian M, Denu JM, Backhed F, Lusis A, Rey FE (2018) Interactions between R. intestinalis and diet modulate atherogenesis in a murine model. Nat Microbiol 3:1461\u20131471. https:\/\/doi.org\/10.1038\/s41564-018-0272-x","journal-title":"Nat Microbiol"},{"key":"5084_CR17","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1099\/00207713-52-6-2141","volume":"52","author":"SH Duncan","year":"2002","unstructured":"Duncan SH, Hold GL, Harmsen HJM, Stewart CS, Flint HJ (2002) Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int J Syst Evol Microbiol 52:2141\u20132146. https:\/\/doi.org\/10.1099\/00207713-52-6-2141","journal-title":"Int J Syst Evol Microbiol"},{"key":"5084_CR18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41575-019-0173-3","volume":"16","author":"ME Sanders","year":"2019","unstructured":"Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA (2019) Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol 16:605\u2013616. https:\/\/doi.org\/10.1038\/s41575-019-0173-3","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5084_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1538\/expanim.22-0057","volume":"72","author":"M Watanabe","year":"2023","unstructured":"Watanabe M, Hiura K, Sasaki H, Okamura T, Sasaki N (2023) Genetic background strongly influences the transition to chronic kidney disease of adriamycin nephropathy in mice. Exp Anim 72:47\u201354. https:\/\/doi.org\/10.1538\/expanim.22-0057","journal-title":"Exp Anim"},{"key":"5084_CR20","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1080\/14786419.2024.2357664","volume":"39","author":"D Peng","year":"2024","unstructured":"Peng D, Huang J, Gao X, Zhou Y, Zhou M (2024) Renoprotective effects of Schoenoplectus tabernaemontani rhizomes aqueous extracts against Adriamycin-induced nephropathy in rats. Nat Prod Res 39:5017\u20135022. https:\/\/doi.org\/10.1080\/14786419.2024.2357664","journal-title":"Nat Prod Res"},{"key":"5084_CR21","doi-asserted-by":"publisher","first-page":"2505114","DOI":"10.1080\/19490976.2025.2505114","volume":"17","author":"M Alizadeh","year":"2025","unstructured":"Alizadeh M, Wong U, Siaton BC, France MT, Patil SA, George L, Hudhud D, Motwani K, Scott WH, Raufman JP, von Rosenvinge EC, Cross RK, Ravel J (2025) The intestinal mucosa-associated microbiota in IBD-associated arthritis displays lower relative abundance of R. intestinalis. Gut Microbes 17:2505114. https:\/\/doi.org\/10.1080\/19490976.2025.2505114","journal-title":"Gut Microbes"},{"key":"5084_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.ijbiomac.2019.11.159","volume":"156","author":"Z Zha","year":"2020","unstructured":"Zha Z, Lv Y, Tang H, Li T, Miao Y, Cheng J, Wang G, Tan Y, Zhu Y, Xing X, Ding K, Wang Y, Yin H (2020) An orally administered butyrate-releasing xylan derivative reduces inflammation in dextran sulphate sodium-induced murine colitis. Int J Biol Macromol 156:1217\u20131233. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.11.159","journal-title":"Int J Biol Macromol"},{"key":"5084_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ijbiomac.2020.03.195","volume":"155","author":"Z Zha","year":"2020","unstructured":"Zha Z, Zhang Z, Wei W, Nie W, Chu W, Huang F, Yue L, Wang S-Y, Yin H (2020) Isolation, structural characterization of polysaccharide from Cephalosporium sinensis mycelia and its anti-nephritic effects in adenine-induced CKD rats. Int J Biol Macromol 155:340\u2013349. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.03.195","journal-title":"Int J Biol Macromol"},{"key":"5084_CR24","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1007\/s12325-019-00974-x","volume":"36","author":"KO Kim","year":"2019","unstructured":"Kim KO, Schwartz MA, Lin OST, Chiorean MV, Gluck M (2019) Reducing cost and complexity of fecal microbiota transplantation using universal donors for recurrent clostridium difficile infection. Adv Ther 36:2052\u20132061. https:\/\/doi.org\/10.1007\/s12325-019-00974-x","journal-title":"Adv Ther"},{"key":"5084_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.26442\/00403660.2021.02.200615","volume":"93","author":"AA Iakupova","year":"2021","unstructured":"Iakupova AA, Abdulkhakov SR, Safin AG, Alieva IM, Oslopova JV, Abdulkhakov RA (2021) Fecal microbiota transplantation: donor selection criteria, storage and preparation of biomaterials (review of current recommendations). Ter Arkh 93:215\u2013221. https:\/\/doi.org\/10.26442\/00403660.2021.02.200615","journal-title":"Ter Arkh"},{"key":"5084_CR26","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","volume":"406","author":"PB Mark","year":"2025","unstructured":"Mark PB, Stafford LK, Grams ME et al (2025) Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406:2461\u20132482. https:\/\/doi.org\/10.1016\/S0140-6736(25)01853-7","journal-title":"Lancet"},{"key":"5084_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejmech.2019.01.043","volume":"166","author":"X Li","year":"2019","unstructured":"Li X, Liu J, Ma L, Fu P (2019) Pharmacological urate-lowering approaches in chronic kidney disease. Eur J Med Chem 166:186\u2013196. https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.043","journal-title":"Eur J Med Chem"},{"key":"5084_CR28","doi-asserted-by":"publisher","first-page":"1193984","DOI":"10.3389\/fmed.2023.1193984","volume":"10","author":"DL Cisneros-Garcia","year":"2023","unstructured":"Cisneros-Garcia DL, Sandoval-Pinto E, Cremades R, Ramirez-de-Arellano A, Garcia-Gutierrez M, Martinez-de-Pinillos-Valverde R, Sierra-Diaz E (2023) Non-traditional risk factors of progression of chronic kidney disease in adult population: a scoping review. Front Med 10:1193984. https:\/\/doi.org\/10.3389\/fmed.2023.1193984","journal-title":"Front Med"},{"key":"5084_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/MNH.0000000000000661","volume":"30","author":"K Sumida","year":"2021","unstructured":"Sumida K, Lau WL, Kovesdy CP, Kalantar-Zadeh K (2021) Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Curr Opin Nephrol Hypertens 30:75\u201384. https:\/\/doi.org\/10.1097\/MNH.0000000000000661","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"5084_CR30","doi-asserted-by":"publisher","first-page":"790783","DOI":"10.3389\/fmed.2021.790783","volume":"8","author":"E Wehedy","year":"2022","unstructured":"Wehedy E, Shatat IF, Al Khodor S (2022) The human microbiome in chronic kidney disease: a double-edged sword. Front Med 8:790783. https:\/\/doi.org\/10.3389\/fmed.2021.790783","journal-title":"Front Med"},{"key":"5084_CR31","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1681\/ASN.2014030288","volume":"26","author":"V Andrade-Oliveira","year":"2015","unstructured":"Andrade-Oliveira V, Amano MT, Correa-Costa M, Castoldi A, Felizardo RJ, de Almeida DC, Bassi EJ, Moraes-Vieira PM, Hiyane MI, Rodas AC, Peron JPS, Aguiar CF, Reis MA, Ribeiro WR, Valduga CJ, Curi R, Vinolo MAR, Ferreira CM, C\u00e2mara NOS (2015) Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 26:1877\u20131888. https:\/\/doi.org\/10.1681\/ASN.2014030288","journal-title":"J Am Soc Nephrol"},{"key":"5084_CR32","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.3390\/ijms23105354","volume":"23","author":"G Magliocca","year":"2022","unstructured":"Magliocca G, Mone P, Di Iorio BR, Heidland A, Marzocco S (2022) Short-chain fatty acids in chronic kidney disease: focus on inflammation and oxidative stress regulation. Int J Mol Sci 23:5354. https:\/\/doi.org\/10.3390\/ijms23105354","journal-title":"Int J Mol Sci"},{"key":"5084_CR33","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1128\/AEM.72.5.3593-3599.2006","volume":"72","author":"A Belenguer","year":"2006","unstructured":"Belenguer A, Duncan SH, Calder AG, Holtrop G, Louis P, Lobley GE, Flint HJ (2006) Two routes of metabolic cross-feeding between Bifidobacterium adolescentis and butyrate-producing anaerobes from the human gut. Appl Environ Microbiol 72:3593\u20133599. https:\/\/doi.org\/10.1128\/AEM.72.5.3593-3599.2006","journal-title":"Appl Environ Microbiol"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-026-05084-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-026-05084-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-026-05084-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:02:34Z","timestamp":1790629354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-026-05084-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5084"],"URL":"https:\/\/doi.org\/10.1007\/s00284-026-05084-w","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All research procedures were conducted in compliance with the ethical standards set forth by China Pharmaceutical University\u2019s Ethics Committee (Approval No: 2022-10-026). All animal experiments were conducted in accordance with the National Guidelines for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"512"}}